Ovarian Cancer

Extended use of paclitaxel delays disease progression in advanced cases

Published in Cancer Weekly, August 5th, 2003

A new study shows that women with advanced ovarian cancer who have responded well to first-line chemotherapy can significantly delay progression of the disease if they continue to take paclitaxel after their initial therapy.

"This is a landmark study that may have a profound impact on the care for a large number of women with ovarian cancer," said Maurie Markman, MD, chairman of the Department of Hematology/Medical Oncology at the Cleveland Clinic, and lead author of the study. "Our findings show, for the first time, that we can significantly increase the amount of time that patients live free from disease, an important goal of anti-cancer therapy."

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-08-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry